NEW YORK, May 13, 2015 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) a clinical-stage immunotherapy company engaged in the development of peptide, gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, recently released fiscal year 2014 financial results. The company reported a weak balance sheet with only $142,000 in cash and an unimpressive income statement recording no revenue and a hefty net loss of $5.53 million.
The company did provide an update on its pipeline as well as provided guidance for the 2015 fiscal year. The company intends to move two of its products into phase 2 clinical trials in 2015 and mentioned that a financing raise will be necessary to continue with its operating plan.
For analyst outlook and recommendation on TapImmune Inc. please follow the link. There is no cost obligation required to view analyst brief.
http://bit.ly/-TPIV-AnalystOutlook
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/despite-unimpressive-company-guidance-shares-soar---brokerbank-securities-300082407.html
SOURCE BrokerBank Securities, Inc.
